A detailed history of Larson Financial Group LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Larson Financial Group LLC holds 910 shares of MRNA stock, worth $37,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares
910
Previous 593 53.46%
Holding current value
$37,091
Previous $70,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$63.64 - $125.14 $20,173 - $39,669
317 Added 53.46%
910 $60,000
Q2 2024

Aug 02, 2024

BUY
$101.21 - $166.61 $56,778 - $93,468
561 Added 1753.13%
593 $70,000
Q4 2023

Feb 01, 2024

SELL
$69.51 - $104.43 $5,769 - $8,667
-83 Reduced 72.17%
32 $3,000
Q3 2023

Nov 03, 2023

SELL
$96.41 - $126.61 $771 - $1,012
-8 Reduced 6.5%
115 $11,000
Q2 2023

Aug 03, 2023

BUY
$118.5 - $160.53 $474 - $642
4 Added 3.36%
123 $14,000
Q2 2022

Aug 04, 2022

BUY
$117.13 - $176.59 $937 - $1,412
8 Added 7.21%
119 $17,000
Q1 2022

May 05, 2022

SELL
$126.46 - $235.05 $8,852 - $16,453
-70 Reduced 38.67%
111 $19,000
Q4 2021

Feb 03, 2022

BUY
$225.82 - $368.51 $9,032 - $14,740
40 Added 28.37%
181 $46,000
Q3 2021

Nov 04, 2021

BUY
$221.9 - $484.47 $8,876 - $19,378
40 Added 39.6%
141 $54,000
Q2 2021

Aug 10, 2021

SELL
$129.91 - $234.98 $4,676 - $8,459
-36 Reduced 26.28%
101 $24,000
Q1 2021

May 06, 2021

BUY
$109.18 - $185.98 $1,200 - $2,045
11 Added 8.73%
137 $18,000
Q4 2020

Jan 14, 2021

SELL
$65.74 - $169.86 $74,154 - $191,602
-1,128 Reduced 89.95%
126 $13,000
Q3 2020

Oct 08, 2020

SELL
$54.34 - $94.85 $16,193 - $28,265
-298 Reduced 19.2%
1,254 $89,000
Q2 2020

Jul 10, 2020

BUY
$29.67 - $80.0 $45,543 - $122,800
1,535 Added 9029.41%
1,552 $100,000
Q1 2020

Apr 09, 2020

BUY
$17.78 - $31.58 $302 - $536
17 New
17 $1,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.9B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Larson Financial Group LLC Portfolio

Follow Larson Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Larson Financial Group LLC with notifications on news.